EMA: REORGANIZATION
THE EUROPEAN MEDICINES AGENCY (EMA) HAS ANNOUNCED THE FIRST DETAILS OF ITS PLANNED REORGANISATION. ROOTED FIRMLY IN THE AGENCY’S OVERALL PUBLIC AND ANIMAL HEALTH MISSION, THE CHANGES REFLECT A RENEWED FOCUS ON THREE KEY ELEMENTS:
Professor Guido Rasi, EMA Executive Director, said, “My aim is to re-shape the EMA to be ready to handle future challenges and give our scientific committees the appropriate support, alongside the expertise from the national agencies, to help them keep delivering high-quality, consistent opinions. These changes are expected to improve the efficiency and effectiveness of our operations…”
In addition to the support to the committees, the changes recognise that the EMA is increasingly a central data and knowledge hub for the European medicines network as a whole. Data held by the Agency will be increasingly shared with partners and stakeholders. The changes also aim towards more coherent support to pharmaceutical companies during the research and development of new medicines, a new contact function for industry, including small and medium-sized enterprises (SMEs), and consolidation of interactions with patients and healthcare professionals.
The new organisational structure is expected to take effect from the beginning of August 2013. The full structure will be implemented over a period of some 18 months.
SOURCE:
EMA: News and Events